To include your compound in the COVID-19 Resource Center, submit it here.

Rigel's fostamatinib meets stage 1 endpoint in Phase II for hemolytic anemia

On Oct. 3, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) reported preliminary data from 17 evaluable patients in stage 1 of the Phase II SOAR trial to treat

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE